Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03698370 · ClinicalTrials.gov registry record · Phase 2
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
A Phase 2 study, sponsored by Andrei Iagaru.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT03698370 is a Phase 2 study that has completed, run by Andrei Iagaru. The registered enrollment target is 27 participants.
The verdict
NCT03698370, a Phase 2 study, has completed, sponsored by Andrei Iagaru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participants with prostate cancer that has come back. Diagnostic procedures, such as gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 PET/MRI, may help find and diagnose prostate cancer and find out how far the disease has spread.
Interventions
- DRUG Gallium Ga 68 DOTA-NeoBOMB1
- DEVICE Gallium Ga 68 PSMA-R2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03698370
The ClinicalTrials.gov registry entry for NCT03698370 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gallium Ga 68 DOTA-NeoBOMB1 is the first listed.
NCT03698370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03698370 about?
NCT03698370 is a clinical study titled "Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer". This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participants with prostate cancer that has come back. Diagnostic procedures, such as gallium Ga 68 DOTA-NeoBOMB1 and galli...
What is the current status of trial NCT03698370?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2020-12-15. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT03698370?
The interventions under investigation include: Gallium Ga 68 DOTA-NeoBOMB1 (DRUG), Gallium Ga 68 PSMA-R2 (DEVICE).
Who is sponsoring clinical trial NCT03698370?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.